Barclays
IMVT icon

Barclays’s Immunovant IMVT Stock Holding History

Barclays’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$1.71K – 5399
2025
Q1 		$1.71K Hold
100
– – ﹤0.01% 5005
2024
Q4 		$2.48K Hold
100
– – ﹤0.01% 5095
2024
Q3 		$2.85K Buy
+100
New +$2.95K ﹤0.01% 5063
2024
Q2 		– Sell
-100
Closed -$3.23K – 5074
2024
Q1 		$3.23K Sell
100
-14,900
-99% -$544K ﹤0.01% 4888
2023
Q4 		$632K Buy
+15,000
New +$552K ﹤0.01% 3735

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's IMVT Position: Q2 2026 in Review

Barclays increased its Immunovant (IMVT) stake by 165% in Q2 2026, buying an estimated $749K and bringing the position to 39,471 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2522.

Barclays first reported a position in IMVT in Q3 2022 and has held it in 14 quarters since. The position peaked at $7.69M in Q4 2024. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Barclays held 39,471 shares of Immunovant worth $1.52M as of Q2 2026.
  • Barclays bought 24,571 Immunovant shares in Q2 2026, an estimated $749K.
  • Immunovant made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2522 holding.
  • Barclays first reported a position in Immunovant in Q3 2022 and has held it in 14 quarters since.
  • Barclays's Immunovant position peaked at $7.69M in Q4 2024.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.